Please assess the completion status of the following clinical trial:

Trial Title: Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically confirmed neuroendocrine tumor metastatic to the liver~  * Well-differentiated or moderately well-differentiated neuroendocrine tumors~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm with conventional techniques or ≥ 10 mm with spiral CT scan~* Symptomatic disease, meeting one of the following criteria:~  * Refractory carcinoid symptoms, defined as Carcinoid Symptom Severity scale \> 2 despite use of octreotide acetate at ≥ 200 mcg subcutaneously three times daily (or 20 mg intramuscularly once monthly) for ≥ 4 weeks~ * Evidence of radiographic progression with either of the following manifestations:~    * Moderate-severe right upper quadrant pain and unintentional weight loss \> 10%~   * Decline in Karnofsky performance status \> 10 points~* At least a 20% increase in the sum of the longest diameters of target lesions in the liver within the past 12 months~* No more than 75% replacement of normal liver by neuroendocrine tumor~* No more than 20% arteriovenous lung shunting on a technetium Tc 99m macro-aggregated albumin nuclear scan~* No equivocal, nonmeasurable, or nonevaluable liver metastasis~PATIENT CHARACTERISTICS:~* Karnofsky performance status 50-100%~* Life expectancy ≥ 6 months~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Creatinine ≤ 1.5 mg/dL~* Bilirubin ≤ 2.0 mg/dL~* Albumin ≥ 3.0 g/dL~* Absolute granulocyte count ≥ 1,500/mm³~* Platelet count ≥ 65,000/mm³~* Hemoglobin \> 9.0 g/dL~* INR ≤ 1.4~* No hepatic arterial anatomy that would preclude the administration of study treatment into the liver~* No nonmalignant disease that would preclude study participation~* No other malignancy within the past 5 years except for cured basal cell carcinoma of the skin or cured carcinoma in situ of the uterine cervix~PRIOR CONCURRENT THERAPY:~* Prior surgery, chemotherapy, or locally ablative technique for the liver cancer allowed~* No prior radiotherapy to the upper abdomen that includes the liver in the treatment field~* No investigational drug or agent/procedure (i.e., participation in another clinical trial) within the past 4 weeks~* No other specific anticancer treatment (other than octreotide acetate) during and for 3 months after completion of study therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sir-Spheres (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).